Skip to main content

Table 2 Multivariable association of IBM score, clinical factors with OS and PFS in the training and validation cohort (likelihood Ratio: Backward stepwise)

From: Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy

Variables Training cohort Validation cohort
HR (95% CI) p HR (95% CI) p
Overall survival
 IBM score 8.636 (3.572–20.876) < 0.001 4.479 (1.707–11.750) 0.068
 T stage* 0. 749 (0.423–1.325) 0.321 2.747 (1.403–5.376) 0.045
 M stage* 1.072 (0.259–4.448) 0.923 1.522 (0.120–19.340) 0.746
 Clinical stage* 1.345 (0.782–2.314) 0.284 0.679(0.283–1.632) 0.387
Progression-free survival
 IBM score 11.471 (3.123–42.134) < 0.001 6.341 (1.667–24.115) 0.007
 Age 0.991 (0.332–1.035) 0.681 0.962 (0.902–1.026) 0.238
 Sex (female vs. male) 0.602 (0.283–1.280) 0.188 0.429 (0.123–1.499) 0.185
 M stage* 1.917 (0.929–3.960) 0.078 0.824 (0.237–2.862) 0.761
 Clinical stage* 1.006 (0.496–2.041) 0.986 1.484 (0.505–4.363) 0.473
  1. IBM, imaging biomarker; CI, confidence interval; HR, hazard ratio
  2. *According to American Joint Committee on Cancer (AJCC) staging system 6th